Rift Valley Fever Treatment Market: Why Does a Disease With a 27.5% Fatality Rate Still Have No Approved Human Vaccine?
The Rift Valley Fever (RVF) treatment market — addressing a mosquito-borne viral hemorrhagic fever affecting both humans and livestock across Africa and the Arabian Peninsula — remains defined by a genuinely stark absence of specific treatment options even as climate-driven outbreak frequency continues rising, with the Rift Valley Fever RVF Treatment Market reflecting a therapeutic...
0 Comments 0 Shares 5 Views 0 Reviews